-
1.发明公开公开(公告)号：US20230272041A1
公开(公告)日：2023-08-31
申请号：US17920174
申请日：2021-04-22
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Mitchell Bigelow , Alexandra Braun , Ann F. Cheung , Jean-Marie Cuillerot , Mark Derose , Asya Grinberg , Eva Gutierrez , Patrick Kirby , Christopher Ryan Morgan , Michael C. Naill , Steven O'Neil , Michael Shifrin , Nicolai Wagtmann
IPC: C07K14/735 , A61K31/7016 , A61K47/14 , A61K9/00 , A61P35/04 , C07K16/28 , A61K38/20 , A61K9/19
CPC classification number: C07K14/70535 , A61K31/7016 , A61K47/14 , A61K9/0019 , A61P35/04 , C07K16/2896 , A61K38/208 , A61K9/19
Abstract: The present invention relates to pharmaceutical formulations for heterodimeric Fc-fused proteins which are advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are dosage regimens for such heterodimeric Fc-fused proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.
-
公开(公告)号：US20220195065A1
公开(公告)日：2022-06-23
申请号：US17682367
申请日：2022-02-28
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Gregory P. Chang , Ann F. Cheung , Jean-Marie Cuillerot , Daniel Fallon , Asya Grinberg , William Haney , Christopher Ryan Morgan , Michael C. Naill , Steven O'Neil , Nicolai Wagtmann , Ronnie Wei
IPC: C07K16/30 , C07K14/725 , C07K16/28 , C07K16/32
Abstract: This disclosure relates to pharmaceutical formulations for multi-specific binding proteins having an epidermal growth factor receptor 2 (ErbB2 or HER2)-binding scFv, an NKG2D-binding Fab, and an antibody Fc domain. Also provided are dosage regimens for such multi-specific binding proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.
-
公开(公告)号：US20230220106A1
公开(公告)日：2023-07-13
申请号：US18062433
申请日：2022-12-06
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Pyae P. Hein , Zong Sean Juo , Xinbi Li , Christopher Ryan Morgan
CPC classification number: C07K16/30 , A61P35/00 , C07K16/2809 , C07K2317/24 , C07K2317/31 , C07K2317/92 , C07K2317/565 , C07K2317/622
Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting 5T4 on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
-
公开(公告)号：US20230203202A1
公开(公告)日：2023-06-29
申请号：US18062453
申请日：2022-12-06
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Mitchell Bigelow , Mark DeRose , Jinyan Du , Robin Friedman , Pyae P. Hein , Stuart William Hicks , Zong Sean Juo , Xinbi Li , Christopher Ryan Morgan
CPC classification number: C07K16/468 , A61P35/04 , C07K2317/565 , C07K2317/55 , C07K2317/622 , C07K2317/53 , C07K2317/31
Abstract: Multispecific binding proteins that bind NKG2D receptor, CD16, and 5T4 are described, as well as pharmaceutical compositions, formulations, and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer.
-
5.发明公开公开(公告)号：US20230250176A1
公开(公告)日：2023-08-10
申请号：US18166769
申请日：2023-02-09
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Ann F. Cheung , Jean-Marie Cuillerot , Mark DeRose , Stacey V. Drabic , Asya Grinberg , Zong Sean Juo , Aaron Levin , Katia Liharska , Lynn Markowitz , Christopher Ryan Morgan , Avni Shah , Michael Shifrin , Nicolai Wagtmann
IPC: C07K16/28 , A61K47/12 , A61K47/26 , A61K39/395 , A61K31/138 , A61K31/167 , A61K31/513 , A61K33/243 , C07K1/22 , A61P35/00
CPC classification number: C07K16/2863 , C07K16/2851 , A61K47/12 , A61K47/26 , C07K16/2818 , C07K16/2827 , A61K39/3955 , A61K31/138 , A61K31/167 , A61K31/513 , A61K33/243 , C07K1/22 , A61P35/00 , C07K2317/31 , C07K2317/622 , C07K2317/55
Abstract: Described herein are pharmaceutical formulations comprising multi-specific binding proteins that bind to NKG2D, CD16, and epidermal growth factor receptor (EGFR); and therapeutic uses of the multi-specific binding proteins and pharmaceutical formulations thereof for treating a disease, for example, cancer, in a patient in need thereof.
-
Patent Agency Ranking
公开(公告)号：US20230034186A1
公开(公告)日：2023-02-02
申请号：US17686238
申请日：2022-03-03
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Jean-Marie Cuillerot , Mark DeRose , Christopher Ryan Morgan , Michael C. Naill , Avni Shah
IPC: A61K39/395 , A61P35/00 , A61K31/573 , A61K31/138 , A61K31/167 , C07K16/28 , C07K16/32 , A61K47/22 , A61K47/26 , A61P1/00 , A61P35/04
Abstract: This disclosure relates to methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen such as HER2. Provided are uses of the multi-specific binding protein in combination with a corticosteroid to reduce the risk of infusion-related reactions. Also provided are uses of the multi-specific binding protein in treating cancer that has low or moderate HER2 expression level. The present disclosure also relates to pharmaceutical formulations comprising the multi-specific binding proteins.
-
公开(公告)号：US20220119534A1
公开(公告)日：2022-04-21
申请号：US17308691
申请日：2021-05-05
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Hemanta Baruah , Gregory P. Chang , Ann F. Cheung , Daniel Fallon , Asya Grinberg , Zong Sean Juo , Christopher Ryan Morgan
Abstract: Described herein are multispecific binding proteins that bind NKG2D receptor, CD16, and CLEC12A, pharmaceutical compositions comprising the multispecific binding proteins, and therapeutic methods useful for the treatment of cancer.
-
公开(公告)号：US12157771B2
公开(公告)日：2024-12-03
申请号：US17308691
申请日：2021-05-05
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Hemanta Baruah , Gregory P. Chang , Ann F. Cheung , Daniel Fallon , Asya Grinberg , Zong Sean Juo , Christopher Ryan Morgan
Abstract: Described herein are multispecific binding proteins that bind NKG2D receptor, CD16, and CLEC12A, pharmaceutical compositions comprising the multispecific binding proteins, and therapeutic methods useful for the treatment of cancer.
-
9.发明公开公开(公告)号：US20230416402A1
公开(公告)日：2023-12-28
申请号：US18177847
申请日：2023-03-03
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Jean-Marie Cuillerot , Mark DeRose , Christopher Ryan Morgan , Michael C. Naill , Avni Shah
IPC: C07K16/32 , C07K16/28 , A61K31/337 , A61K39/395 , A61P35/00
CPC classification number: C07K16/32 , C07K16/2851 , C07K16/283 , C07K16/2818 , A61K31/337 , A61K39/3955 , A61P35/00 , C07K2317/622
Abstract: This disclosure relates to methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen such as HER2, and pharmaceutical compositions thereof. Also provided are uses of the multi-specific binding protein in combination with an anti-PD-1 therapeutic and/or cytoskeletal disrupting chemotherapeutic agent.
-
公开(公告)号：US20230279121A1
公开(公告)日：2023-09-07
申请号：US18040501
申请日：2021-08-05
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Asya Grinberg , Zong Sean Juo , Katia Liharska , Christopher Ryan Morgan
CPC classification number: C07K16/2863 , C12N15/63 , A61P35/00 , C07K2317/565 , C07K2317/92
Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting EGFR on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.017 seconds)
